Vempati Prakash, Popel Aleksander S, Mac Gabhann Feilim
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Institute for Computational Medicine and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19. doi: 10.1016/j.cytogfr.2013.11.002. Epub 2013 Nov 27.
The regulation of vascular endothelial growth factor A (VEGF) is critical to neovascularization in numerous tissues under physiological and pathological conditions. VEGF has multiple isoforms, created by alternative splicing or proteolytic cleavage, and characterized by different receptor-binding and matrix-binding properties. These isoforms are known to give rise to a spectrum of angiogenesis patterns marked by differences in branching, which has functional implications for tissues. In this review, we detail the extensive extracellular regulation of VEGF and the ability of VEGF to dictate the vascular phenotype. We explore the role of VEGF-releasing proteases and soluble carrier molecules on VEGF activity. While proteases such as MMP9 can 'release' matrix-bound VEGF and promote angiogenesis, for example as a key step in carcinogenesis, proteases can also suppress VEGF's angiogenic effects. We explore what dictates pro- or anti-angiogenic behavior. We also seek to understand the phenomenon of VEGF gradient formation. Strong VEGF gradients are thought to be due to decreased rates of diffusion from reversible matrix binding, however theoretical studies show that this scenario cannot give rise to lasting VEGF gradients in vivo. We propose that gradients are formed through degradation of sequestered VEGF. Finally, we review how different aspects of the VEGF signal, such as its concentration, gradient, matrix-binding, and NRP1-binding can differentially affect angiogenesis. We explore how this allows VEGF to regulate the formation of vascular networks across a spectrum of high to low branching densities, and from normal to pathological angiogenesis. A better understanding of the control of angiogenesis is necessary to improve upon limitations of current angiogenic therapies.
血管内皮生长因子A(VEGF)的调控在生理和病理条件下对众多组织中的新生血管形成至关重要。VEGF有多种异构体,通过可变剪接或蛋白水解切割产生,具有不同的受体结合和基质结合特性。已知这些异构体可引发一系列以分支差异为特征的血管生成模式,这对组织具有功能意义。在本综述中,我们详细阐述了VEGF广泛的细胞外调控以及VEGF决定血管表型的能力。我们探讨了释放VEGF的蛋白酶和可溶性载体分子对VEGF活性的作用。虽然诸如MMP9之类的蛋白酶可以“释放”与基质结合的VEGF并促进血管生成,例如作为致癌作用中的关键步骤,但蛋白酶也可以抑制VEGF的血管生成作用。我们探究了决定促血管生成或抗血管生成行为的因素。我们还试图理解VEGF梯度形成的现象。强大的VEGF梯度被认为是由于从可逆基质结合扩散的速率降低所致,然而理论研究表明,这种情况在体内无法产生持久的VEGF梯度。我们提出梯度是通过隔离的VEGF的降解形成的。最后,我们综述了VEGF信号的不同方面,如浓度、梯度、基质结合和NRP1结合如何对血管生成产生不同影响。我们探究了这如何使VEGF能够在从高到低分支密度的范围内,以及从正常到病理血管生成的过程中调节血管网络的形成。更好地理解血管生成的控制对于改善当前血管生成疗法的局限性是必要的。